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Next Generation of Advanced Non-Small Cell Lung Cancer 
Therapy: Targeted and Immuno-Therapies 
Sze Wah Samuel Chan,1 Elliot Smith.1* 
Abstract 
Lung cancer is one of the deadliest cancers in the world. Current clinical trials are focused on developing the next generation of therapies that target novel 
anti-cancer mechanisms. One approach is to prime the immune system, as the cancer has been known to suppress immune cells in the tumor 
microenvironment. Using immunotherapy, the immune system can be unleashed and suppress the cancer’s growth. Another pathway is targeting known 
oncogenic genes that are important for the cancer’s growth and survival. In lung cancer, the epidermal growth factor receptor and several other mutated 
proteins are targets of small-molecule inhibitors that have been shown to drastically improve patient survival and quality of life. Discussed in this review 
are broad highlights of the different immunotherapies and small molecule targeted therapies that have been studied in the latest clinical trials for lung 
cancer. 
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Introduction 
Globally, cancer is increasingly one of the greatest health burdens, with 
an estimated 20% probability of being diagnosed with cancer before 
age 75 and a 10% chance of dying from it.1 According to GLOBOCAN in 
2018, lung cancer had the highest incidence, with nearly 2 million cases 
and the highest mortality at almost 1.7 million deaths. In the United 
States, similar trends were observed where 234,030 lung cancer cases 
were diagnosed, accounting for 25% of cancer deaths.1  
 
Lung cancer is histologically divided into small cell lung carcinoma 
(~15% of lung cancers) and non-small cell lung carcinoma (NSCLC) (85% 
of lung cancers).2 NSCLC is further subdivided into squamous, 
adenocarcinoma, and large cell carcinoma. These histopathological 
divisions help decide further investigations and management. Many of 
the development of the next generation of medical therapies has 
focused on stage IV, metastatic lung cancers and will be the focus of 
this review. Until recently, the first-line chemotherapy regimen for 
metastatic NSCLC is chemotherapy with two drugs, one of which is a 
platinum agent (known as platinum-doublet chemotherapy); where 
appropriate, maintenance chemotherapy with a single agent may take 
place after the end of 4-6 rounds of platinum-doublet chemotherapy.3,4 
Few effective treatments are available after disease progression and 
mainly involve single-agent chemotherapy such as docetaxel.3  
 
For treatment-naïve patients, identification of who benefits from 
immunotherapy is contingent on several main factors: lack of a driver 
mutation (e.g. EGFR or ALK as immunotherapies are likely less effective 
than targeted therapy in this population) and biomarker status.5 PD-
L1/PD-1 is the most commonly used biomarker status for lung cancer 
as the approved therapies all target this immune blockade.6 The PD-
L1/PD-1 axis is a mechanism by which cancer cells induce T cell anergy 
and exhaustion, and avoid anti-tumor immune cells. PD-L1/PD-1 
antibodies block this interaction and allow the immune system to 
recognize and then suppress the cancer cells.7 The goal of this review 
is to provide a broad yet comprehensive overview of the different next-
generation cancer therapies in NSCLC and provide a summary of the 
evidence rationalizing each therapy. The following section will focus on 
immune modulators that re-educate the immune system to attack the 
cancer cells based on phase III clinical trials data. The second section 
will discuss targeted therapies for lung cancers with driver mutations. 
Finally, the last section will propose an algorithm for treatment decision 
making based on the current evidence. 
 
The adverse events and clinical trials described in this review use the 
Common Terminology for Adverse Events (CTCAE) terminology system 
which aims to unify the nomenclature in assessing the severity of each 
adverse event.  Grade 1 represents mild adverse events and 
intervention is not needed to grade 4 where there are life-threatening 
consequences requiring immediate intervention.8,9 Grade 5 is reserved 
for cases where the adverse event led to death. An example of a grade 
1 event in vomiting means it requires no intervention a grade 2 event 
is determined by the need for outpatient IV hydration, a grade 3 event 
requires hospitalization or tube-feeding and grade 4 carries life-
threatening consequences. Table 1 has examples of different common 
adverse events reported in oncology clinical trials and their grading 
definitions. 
 
Immunotherapy with Monotherapy 
Nivolumab as second-line monotherapy for metastatic NSCLC 
Nivolumab is a human IgG4 anti-PD-1 monoclonal antibody and has 
been approved for second-line therapy regardless of PD-L1 status. In 
the CheckMate 017 and CheckMate 057 trials, nivolumab was compared 
to docetaxel for patients with disease progression after first-line 
therapy for both squamous and non-squamous histology. Nivolumab 
lowered the risk of death compared to docetaxel in squamous (hazard 
ratio (HR) 0.59, 95% confidence interval (CI) 0.44 to 0.79, P <0.001, 
minimum follow-up was 11 months) and non-squamous (HR 0.73, 95% 
CI 0.59 to 0.89, P = 0.002, minimum follow-up was 13.2 months) cell 
types.10,11 CheckMate 026 evaluated nivolumab monotherapy in the first 
line, which showed non-significant differences in overall and 
progression-free survival.12 However, the nivolumab group reported 
18% grade 3-4 adverse events as opposed to 51% in the standard 
chemotherapy group, mainly with more fatigue and hematological 
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adverse events such as neutropenia, thrombocytopenia, and anemia in 
the chemotherapy group.12 
 
Atezolizumab monotherapy as second-line therapy for metastatic NSCLC 
Atezolizumab is a humanized monoclonal IgG1 PD-L1 antagonist. The 
OAK trial demonstrated in second-line therapy that atezolizumab 
improved overall survival (OS) (HR 0.73, 95% CI 0.62 to 0.87, P = 0.0003) 
compared to docetaxel with a median follow-up of 21 months.13 Similar 
to nivolumab, the difference was significant regardless of PD-L1 tumor 
expression. Fewer grade 3-4 adverse events were observed with 
immunotherapy (15% vs. 43%), where chemotherapy had more 
hematological adverse events such as anemia, neutropenia, and febrile 
neutropenia.13 
 
Table 1. Common Terminology for Adverse Events (CTCAE) v5.0 examples. 
 
Grade 1 Grade 2 Grade 3 Grade 4 
Rash – Maculo-papular 
<10% Body 
surface area 
(BSA) 
10-30% BSA, limiting 
activities of daily 
living, or >30% BSA 
but no or mild 
symptoms of 
burning, pruritis, or 
tightness 
>30% BSA with moderate 
to severe symptoms; 
limiting self-care ADLs 
Grade not 
available 
Diarrhea 
<4 stools per 
day over 
baseline, 
mile 
increase in 
ostomy 
output 
Increase of 4-6 stools 
per day over 
baseline, a moderate 
increase in ostomy 
output, limits 
instrumental ADL 
Increase of >7 stools per 
day over baseline, 
hospitalization is 
indicated, severe 
increase in ostomy 
output, limiting self-care 
ADLs 
Life-
threatening, 
urgent 
intervention 
required 
Neutropenia 
<LLN 
including 
1500/m3, 1.5 
x 109 / L 
<1500 – 1000/mm3, 
<1.5 – 1.0 x 109 / L 
<1000 – 500/mm3, <1.0 – 
0.5 x 109 / L 
<500/mm3, 
<0.5 x 109 / 
L 
Anemia 
Hemoglobin 
< LLN, 
including 
<10.0 g/dL, 
<6.2 mmol/L, 
<100 g/L 
Hemoglobin <10.0-8.0 
g/dL, <6.2-4.9 mmol/L, 
<100-80 g/L 
Hemoglobin <8.0 g/dL, 
<4.9 mmol/L, <80 g/L; 
transfusion is indicated 
Life-
threatening, 
urgent 
intervention 
required 
 
All definitions were extracted directly from the Common Terminology 
for Adverse Events (CTCAE) v5.0, developed by the National Cancer 
Institute (NCI) Cancer Therapy Evaluation Program (CTEP) published in 
November 2017, https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm). 
Each adverse event is graded according to severity, where grade 1 is 
the least severe with no intervention to grade 4, which requires urgent 
intervention and grade 5 is reserved for deaths related to the adverse 
event. Self-care activities of daily living (ADL), according to CTCAE, refer 
to bathing, dressing, undressing, feeding self, using the toilet, taking 
medication and not bedridden. Instrumental ADLs refer to preparing 
meals, shopping for groceries or clothing, using the telephone or 
managing money.  
 
Pembrolizumab as monotherapy in first- or second-line metastatic 
NSCLC 
Pembrolizumab, a humanized monoclonal IgG4 PD-1 receptor 
antagonist, was first tested in 2016 where the Keynote 10 trial compared 
pembrolizumab vs. docetaxel in the second-line, which showed 
superior overall survival (HR 0.61, 95% CI 0.49 to 0.75, P <0·0001, median 
follow-up was 13.1 months) driven mainly by patients with PD-L1 
immunohistochemical staining of at least 50% (OS HR 0.50, 95% CI 0.36-
0.70,P <0.0001) for which it was mainly powered to detect.14 In the same 
year, Keynote 24, with a median follow-up of 11.2 months, confirmed 
the benefit in the ≥ 50% PD-L1 setting now in the first-line setting. 
Pembrolizumab treatment induced longer overall survival (HR 0.60, 95% 
CI 0.41 to 0.89, P = 0.005) compared to platinum-based doublet 
therapy.15 Furthermore, grade 3-5 adverse events were less in the 
immunotherapy group (26.6% vs. 53.3%), which were similar to 
nivolumab and atezolizumab, where the chemotherapy group had more 
hematological suppression. One key point from the trial was that 
immunotherapies demonstrated more immune-related adverse events 
such as more severe skin reactions, pneumonitis and colitis.15 Keynote 
42 was a follow-up trial that indicated that tumors with ≥ PD-L1 1% 
treated with pembrolizumab showed superior overall survival (HR 0.81, 
95% CI 0·71 to 0·93, P=0·0018) at a median follow-up of 12.8 months 
with a similar side effect profile demonstrated in the previous trials.16 
 
Sequential Durvalumab Monotherapy after Chemoradiation in 
Unresectable Stage III NSCLC 
Durvalumab is an IgG1 kappa monoclonal antibody against PD-L1 that 
was investigated in the PACIFIC trial in stage III surgically unresectable 
NSCLC without disease progression after ≥ 2 cycles of platinum-based 
chemoradiotherapy compared to placebo. Durvalumab-treated patients 
demonstrated superior overall survival (HR 0.68, 99.73% CI 0.47 to 0.997, 
P = 0.0025, median follow-up 25.2 months). For grade 3 or 4 adverse 
events due to any cause, 30.5% of the durvalumab treatment group 
reported these events compared to 26.1% in the placebo group. Most 
of the grade 3-4 event differences were due to increased pneumonia 
and radiation pneumonitis in the immunotherapy group.17,18 
Durvalumab is unique as the only approved consolidation 
immunotherapy single agent for NSCLC. 
 
Immunotherapy Combination Therapies 
Immunotherapy with Chemotherapy for first-line metastatic NSCLC 
The latest clinical trials have expanded beyond the monotherapy realm 
to investigate more effective front-line therapies. One strategy is to 
combine chemotherapy and immunotherapy, and there is evidence to 
suggest they can work synergistically in melanoma trials.19,20 In the 
first-line setting, Keynote 189 compared standard platinum-based 
chemotherapy ± pembrolizumab in non-squamous NSCLC. The 
immunotherapy with chemotherapy group demonstrated better overall 
survival (HR 0.49, 95% CI 0.38 to 0.64, P <0.001) and the trend was 
preserved regardless of PD-L1 expression, where median follow-up was 
10.5 months.21 Adverse events of grade 3 or higher were found in 67.2% 
for the combination group compared to 65.8% for the chemotherapy 
group. The main difference in grade 3 or higher events in the 
combination group was more febrile neutropenia.21 Keynote 407 
(median follow-up of 7.8 months), which studied carboplatin + 
paclitaxel ± pembrolizumab in squamous NSCLC, showed similar 
improvements for the combination group (HR 0.56, 95% CI 0.45 to 0.70, 
P <0.001), with similar number of grade 3 or higher adverse events 
(69.8% vs. 68.2%) with more pneumonitis and autoimmune hepatitis in 
the combination group.22  
 
One of the CheckMate 227 secondary goals compared first-line 
platinum-doublet chemotherapy ± nivolumab in the <1% PD-L1 
population, which showed improved OS compared to chemotherapy 
alone (HR 0.78, 95% CI 0.60 to 1.02, P = 0.035, minimum follow-up was 
29.3 months).23 IMpower 131 was a trial comparing first-line carboplatin 
and nab-paclitaxel ± atezolizumab in squamous NSCLC, where there was 
improved progression-free survival (HR 0.715, 95% CI, 0.603 to 0.848; P 
= 0.0001) but no differences in overall survival (P = 0.16).24,25 The 
IMpower130 was a similar trial for non-squamous histological subtypes 
and reported at the European Society of Medical Oncology (ESMO) 2018 
that atezolizumab + carboplatin and nab-paclitaxel had superior OS (HR 
0.79, 95% CI 0.64 to 0.98, P = 0.033) and PFS (HR 0.64, 95% CI 0.54 to 
0.77; P <0.0001) compared to carboplatin and nab-paclitaxel alone.26 
 
Dual Immunotherapy 
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is another target 
of immunotherapy blockade, which combined with PD-L1 blockade, has 
demonstrated improvement in metastatic melanoma.27 The rationale is 
to target different T-cell activation pathways to induce a more robust 
tumor response. In CheckMate 227, another secondary goal was to 
compare nivolumab and ipilimumab treatment with nivolumab 
monotherapy in PD-L1 ≥1%. This comparison showed trends towards 
benefit for the PD-L1 ≥1% population (HR 0.90, 95% CI 0.76-1.07) and PD-
L1 ≥50% (HR 0.87, 95% CI 0.68-1.12), but there were more grade 3-4 
events in the dual immunotherapy group compared to the 
monotherapy group (35.5% vs. 19.4%). More specifically it included 
more rash, pruritis, diarrhea and adverse events with suspected 
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immune etiology affecting the pulmonary, gastrointestinal, skin and 
endocrine systems.23 
 
The MYSTIC trial investigated patients with PD-L1 ≥ 25% with a 
durvalumab and tremelimumab (anti-CTLA-4) combination in the first-
line setting. Unfortunately, the immunotherapy combo was 
unsuccessful in showing PFS or OS improvements over chemotherapy 
but had less grade 3-4 treatment adverse event profiles (22.1% in 
combination vs. 33.8% in chemotherapy).28 The NEPTUNE trial 
(durvalumab + tremelimumab vs. chemotherapy) includes ALK and 
EGFR patients, and is set to reveal results soon.29 
 
Immune-Related Adverse Events in 
Immunotherapies 
Immunotherapies are not harmless despite a safer side effect profile 
compared to chemotherapy. Physicians caring for patients undergoing 
immunotherapies must be keenly aware of the unique and dangerous 
side effects compared to chemotherapy patients (Table 2). The unique 
danger in immune-oncology is an overstimulation of the immune 
system, which can induce an autoimmune condition. The most common 
immune-related adverse event (irAE) is dermatological rash/pruritis, 
with an estimated prevalence of 30% in nivolumab or pembrolizumab 
patients.30 Grade 1 toxicities do not necessarily necessitate stopping 
treatment and can be treated with topical steroids or symptomatic 
systemic treatment. Serious irAEs that require clinicians to be vigilant 
about are colitis, pneumonitis, endocrinopathies, neurological 
syndromes, and cardiovascular compromise (Table 2). For all toxicities, 
grade 1 events should be monitored for progression while grade 2 and 
above may necessitate withholding treatment or permanently 
discontinuing treatment and immunosuppressive treatment depending 
on the specific irAE.31 Specific irAE risk stratification and treatment 
strategies are summarized in the American Society of Clinical Oncology 
Clinical Practice Guidelines and the Society for Immunotherapy of 
Cancer (SITC) Toxicity Management Working Group.30,31 Due to the 
potential for high morbidity and mortality associated with pneumonitis, 
colitis, neurological syndromes and cardiovascular toxicity, these 
warrant consideration of immediate discontinuation and referral to 
additional specialists. The mainstay of systemic treatment for grade 2 
and above adverse events is corticosteroids, such as prednisone at 0.5-
2 mg/kg/day depending on the grade of the toxicity, along with 
appropriate prophylaxis therapies.31 If refractory, immunomodulatory 
therapies could serve as the next step; for instance, infliximab has been 
reported in the use of refractory colitis.31–33 
 
Targeted Agents for NSCLC Patients Carrying 
Actionable Mutations 
Epidermal Growth Factor Receptor 
Epidermal Growth Factor Receptor (EGFR), a receptor tyrosine kinase 
responsible for cell proliferation and survival, is one of the most 
commonly identified driver mutations in NSCLC. The prevalence of EGFR 
aberrations in NSCLC varies drastically based on geographical 
distribution, varying from 10% in North American and Western European 
cases to 30% in East Asian cases.34,35 Studies have reported a higher 
prevalence in females and non-smokers.34,36 From a histologic 
perspective, it is most frequently seen in adenocarcinomas compared 
to any other NSCLC histologic subtype, with a rate of 30% compared to 
2% of another diagnosis.35,36 The most common of these intracellular TK 
mutations include the L858R mutation in exon 21, or short in-frame 
deletions in exon 19, which both contribute 90% of the aberrations in 
this domain.  
 
Gefitinib 
Gefitinib is an EGFR inhibitor that competitively inhibits ATP. It is 
approved for first-line therapy of EGFR+ metastatic NSCLC. The IRESSA 
Pan-Asian Study (IPASS) was a seminal phase III trial demonstrating 
remarkable efficacy. In the EGFR+ subgroup, gefitinib was superior to 
carboplatin-paclitaxel, with an improvement in PFS (HR 0.48, 95% CI 
Table 2. Potential Adverse Events for Immunotherapies for Oncology 
Treatment. 
 
Common Adverse 
Events 
Uncommon 
Adverse Events 
Indications to Stop 
Treatment 
Maculopapular 
rash 
Renal involvement Pneumonitis 
Pruritis Neurological 
syndromes 
Colitis 
Fatigue Exocrine pancreas 
involvement 
Neurological syndromes 
Infusion-related 
reactions 
Cardiovascular 
toxicity 
Potentially for cardiovascular 
toxicity  
Diarrhea Hematological related Grade 2-4, reassessment for 
restarting treatment after 
symptom resolution 
Hepatitis Ophthalmological 
inflammation 
 
Hypothyroidism Myositis  
Hypophysitis Pneumonitis  
Arthralgia  Colitis  
 
Legend: The table was adapted from the Society for Immunotherapy of Cancer (SITC) 
Toxicity Management Working Group, reference 31: Puzanov I, Diab A, Abdallah K, 
Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune 
checkpoint inhibitors: Consensus recommendations from the Society for 
Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother 
Cancer. 2017;5(1):1–28. 
 
0.36-0.64, P<0.001) and overall survival (HR 0.78, 95% CI, 0.50-1.20).37 
Median follow-up in this study was 527 days. In the EGFR- subset, 
patients treated with the gefitinib showed a worse PFS (HR 2.85, 95% CI 
2.05-3.98, P<0.001).37 From a toxicity perspective, in IPASS, gefitinib was 
associated with fewer grade 3-4 adverse events (28.7% vs 61.0%).37 The 
most common toxicities for gefitinib included rash, diarrhea and 
mucositis, while neurotoxicities and hematologic toxicities were 
significantly lower compared to chemotherapy.37 
 
Erlotinib 
Erlotinib, like gefitinib, is an EGFR inhibitor and has a similar 
mechanism to gefitinib. It is approved for locally advanced or 
metastatic EGFR+ NSCLC. In the EURTAC trial, erlotinib was compared to 
cisplatin-docetaxel or gemcitabine in a first-line setting and found to 
have a significantly improved PFS (HR 0.16, 95% CI 0.10-0.26, P<0.0001).38 
The median follow-up in this study was 18.9 months in the erlotinib 
group. Other phase III trials using erlotinib in the first-line setting 
compared against platinum-based combination chemotherapy 
regimens, such as OPTIMAL and ENSURE, have shown similar results 
with erlotinib achieving a significant improvement in PFS.39,40 Erlotinib 
has also been studied as a combination therapy through the FASTACT 
trial where erlotinib intercalated with gemcitabine and platinum 
therapy versus chemotherapy with placebo was compared in patients 
with NSCLC. The erlotinib combination, in EGFR+ mutated NSCLC, 
showed a significant increase in PFS (HR 0.25, 95% CI 0.16-0.39, 
P<0.0001).41 Erlotinib intercalated chemotherapy also showed significant 
improvements in overall survival (HR 0·48, 95% CI 0.27–0.84, P = 
0·0092).41 Median follow-up in the erlotinib plus chemotherapy was 28.2 
months. In the EURTAC trial, erlotinib had fewer grade 3-4 adverse 
events than chemotherapy (45% vs 65%). Rash and elevated 
aminotransferase concentrations were the most frequent adverse 
events in the erlotinib group compared to neutropenia and anemia 
being the most frequent adverse events in the chemotherapy group.38  
 
Afatinib 
Afatinib is a second-generation EGFR tyrosine kinase inhibitor (TKI) and 
exhibits its effect by irreversibly binding to the kinase domain in all 
erbB family tyrosine kinases. LUX-LUNG-1 was a phase IIB/III trial that 
studied afatinib versus placebo in NSCLC patients who have previously 
received chemotherapy and have failed on a previous EGFR TKI. While 
there was no significant difference in OS, PFS was improved (HR 0.38, 
95% CI 0.31–0.48, P<0·0001) with afatinib, and these patients were 
followed for an estimated two years.42 In addition, in patients who 
previously developed resistance, PFS was significantly improved by 
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afatinib treatment, which supports its role as a treatment-following 
resistance development in first-line EGFR TKIs. Adverse events were 
similar between afatinib and chemotherapy, where the most frequently 
encountered events include rash, diarrhea and mucositis. In LUX-LUNG-
8, afatinib showed improved PFS and OS compared to erlotinib.43  
 
Osimertinib 
Osimertinib is a third-generation EGFR TKI and, similar to afatinib, acts 
by binding irreversibly to the EGFR receptor. Intriguingly, this drug 
shows a pharmacological effect in patients with sensitizing mutations 
such as exon 19 deletion or exon 21 L858R as well as patients with the 
exon 21 T790M mutation, typically conferring resistance to EGFR TKIs. In 
the AURA3 trial, osimertinib was compared to platinum-pemetrexed in 
patients who had previously failed on first-line EGFR TKI. Osimertinib 
showed superior progression-free survival (HR 0.30, 95% CI 0.23-0.41, 
P<0.001) and fewer grade 3-4 adverse events than chemotherapy (23% 
vs 47%). Median follow-up for all patients in this study was 8.3 months. 
The most common side effects within the osimertinib group were 
paronychia, rash and diarrhea compared to anemia and GI-related 
adverse events, which were the most common toxicities seen in the 
chemotherapy group.44 The FLAURA trial showed osimertinib provided a 
significant improvement in progression-free survival versus gefitinib or 
erlotinib in the first-line setting (HR 0.46, 95% CI, 0.37-0.57, P<0.001). 
Median follow-up for the osimertinib group was 15 months and 9.7 
months in the standard EGFR-TKI group.45 The drug has recently been 
approved for first-line treatment of metastatic EGFR+ NSCLC. 
 
NSCLC patients carrying Anaplastic Lymphoma Kinase translocations 
Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase 
normally found on chromosome 2. Under normal circumstances, it is 
expressed at low levels in the small intestines, neural tissue, male 
testes and has a role in neural development.46 It is found mutated and 
fuses with other partner genes in approximately 1-5% of NSCLC cases 
and, similarly to EGFR, is found in predominantly non-smokers and 
adenocarcinoma histology.47  
 
Crizotinib 
Crizotinib is a TKI that inhibits ALK. PROFILE-1007 was a phase III study 
comparing crizotinib to chemotherapy in ALK-positive NSCLC following 
failure on the first-line, platinum-based doublet chemotherapy. 
Crizotinib showed a significant PFS improvement to chemotherapy (HR 
0.49, 95% CI 0.37-0.64, P<0.001).48 The median follow-up in the crizotinib 
group was 12.2 months. Crizotinib also showed a more tolerable toxicity 
profile compared to chemotherapy, where the most common adverse 
events were visual disorder, GI-related symptoms, and elevated 
aminotransferase levels. PROFILE 1014 studied crizotinib in 
chemotherapy-naïve ALK-positive NSCLC and found PFS to be 
significantly improved in the crizotinib group compared to 
chemotherapy (HR 0.45; 95% CI 0.35-0.60, P<0.001, median follow-up of 
17.4 months).49 
 
Ceritinib 
Ceritinib is a next-generation TKI approved for ALK mutated NSCLC. As 
a more potent inhibitor, ceritinib has displayed activity in certain cases 
that have developed resistance and progressive disease on crizotinib. 
The ASCEND-1 trial studied ceritinib in patients who were previously 
treated and progressed on crizotinib, and found that 56% responded 
(95% CI, 49-65%), and the median PFS was 6.9 months (95% CI, 5.6-8.7 
months). Median follow-up was 11.1 months. The most common 
adverse events included GI-related symptoms, primarily grade 1 or 2 in 
severity, including elevated aminotransferase concentrations.50  
 
Alectinib 
Alectinib is another next-generation ALK-targeted TKI that has shown 
activity against crizotinib-resistant NSCLC. Of particular interest, this 
drug is not a P-Glycoprotein substrate and therefore, can achieve 
significantly improved intracranial concentrations for targeting CNS 
metastases. Alectinib was then compared to crizotinib in the first-line 
setting in two clinical trials, J-ALEX and ALEX, with improved PFS for 
alectinib and 12-month event-free survival rate, which was 68.4% vs. 
48.7% (95% CI, 61-76% vs. 40-57%).51 Furthermore, CNS progression 
occurred in 12% of the alectinib group compared to 45% of the crizotinib 
group. Median follow-up in this study was 17.6 months in the crizotinib 
group and 18.6 months in the alectinib group. Overall, alectinib had 
more adverse events than crizotinib; however, when comparing based 
on severity, alectinib had marginally fewer grade 3-5 adverse events 
(41% vs 50%). The most common adverse events in the alectinib group 
include GI-related symptoms, elevated aminotransferase 
concentrations, peripheral edema and myalgia. Most impressively, the 
ALEX trial found a PFS of over 34 months compared to 12 months in 
patients treated with crizotinib, setting the stage for a change in first-
line recommendations to alectinib soon.51  
 
Brigatinib 
Brigatinib is an additional next-generation ALK TKI that has shown 
activity in this NSCLC subtype. In the ALTA-1L phase III trial, brigatinib 
was compared to crizotinib in a front-line setting. Median follow-up in 
this trial was 11 months in the brigatinib group and 9.3 months in the 
crizotinib group. Brigatinib was found to be more efficacious for PFS 
(HR 0.49, 95% CI 0.33-0.74, P<0.001).52 In addition, brigatinib was found 
to show increased activity against CNS lesions with an observed 
response rate of 78% (95% CI, 52-94%) compared to 29% (95% CI, 11-
52%) in the crizotinib group.52 The brigatinib group had a higher 
frequency of grade 3-5 adverse events, occurring in 61% of patients 
compared to 55% of the crizotinib group, the most common of which 
were elevated creatine kinase, elevated lipase levels and 
hypertension.52  
 
Treatment Algorithm for Advanced NSCLC 
The treatment of patients with metastatic or unresectable NSCLC is 
rapidly evolving and increasingly complex based on the most available 
data. The immunotherapy summary is adapted from the expert opinion 
provided by the Society for Immunotherapy of Cancer 2018 NSCLC 
consensus statement as well as the compilation of the targeted therapy 
trials highlighted above (Figure 1).53 
 
With the diagnosis of advanced NSCLC, standard staging should first be 
conducted if not already completed. Following that, driver mutation 
analysis, histological subtype and PD-L1 expression are some of the 
most basic molecular profiling to decide on initial treatment decisions. 
 
For patients with non-squamous histology and an actionable driver 
mutation, TKI therapy would be initiated first in almost all cases. For 
EGFR positive patients, afatinib, erlotinib, gefitinib and osimertinib may 
be used in first-line with osimertinib used in treatment-resistant cases. 
For ALK-fusion tumors, crizotinib is considered first-line with ceritinib 
and alectinib following progression; however, this is likely to change 
soon given the superiority of alectinib in both efficacy and toxicity 
profiles in the first-line setting because of the ALEX trial results. Also, 
upcoming trial data of lorlatinib, a fifth ALK inhibitor, has some 
preliminary evidence of efficacy in patients who have failed multiple 
other ALK inhibitors; however, phase III trial data is not yet available.54 
 
For tumors carrying ROS1 fusions, there is evidence that crizotinib and 
lorlatinib are effective; entrectinib is another drug that is showing 
promise.55,56 For BRAF-mutated tumors, dabrafenib and trametinib can 
be considered.  
 
For patients who have failed targeted therapy, platinum doublet 
therapy should be considered as second-line therapy due to previous 
poor efficacy of immunotherapy in this subpopulation.53 Third-line 
would include immunotherapy monotherapy, including atezolizumab, 
nivolumab or pembrolizumab. Patients with no identifiable, actionable 
driver mutation have the choice for pembrolizumab/immunotherapy 
alone or a combination for first-line therapy. While Checkmate 227 
showed some initial promising data for dual-immunotherapy vs 
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monotherapy, it was not powered enough to detect a meaningful 
difference, and there were some initial concerns of immune-related 
adverse events. For patients with PD-L1 < 50%, there is evidence for 
pembrolizumab with chemotherapy for both squamous (carboplatin + 
nab-paclitaxel or paclitaxel) and non-squamous cell histology (platinum 
+ pemetrexed). For PD-L1 ≥ 50% non-squamous cell, there is benefit 
from either pembrolizumab monotherapy or pembrolizumab + 
chemotherapy that is dependent on symptomology and how fast the 
cancer is progressing. For PD-L1 ≥ 50% in squamous cells, there are 
similar choices but less strong evidence for combination therapy. 
Pending the peer-reviewed published results of IMpower 130, 
atezolizumab + carboplatin and nab-paclitaxel may be an alternative 
option for squamous cell carcinomas.  
 
For patients who progress on immunotherapy, the second-line would 
include either pemetrexed (non-squamous) or docetaxel (squamous) 
based on standard second-line chemotherapy regiments. Furthermore, 
with patients with isolated sites of progression or “oligoprogression,” 
there is a consideration for local therapy, but the management is not 
within the scope of this review. 
 
Conclusion 
In summary, immunotherapies have transformed metastatic lung 
cancer care by providing more durable responses and more effective 
responses compared to traditional chemotherapy. There is no doubt 
about the clinical benefit of immunotherapies; however, the current 
question is identifying the patients who would benefit. Only 40-50% of 
PD-L1 positive patients clinically benefit from immunotherapy, while 
15% of PD-L1 negative patients also benefit.57 This highlights the 
complexity of the mechanism of these immunomodulatory drugs that 
are not explained fully by PD-L1 expression. Tumor mutational burden, 
cytotoxic T cell infiltration, immune gene signatures and immune 
compositive biomarkers are emerging biomarkers.58 For targeted 
therapies, the race between drug targets and resistance will continue, 
and novel strategies for identifying resistance and combination therapy 
will be the key to future success in controlling these oncogene-addicted 
cancers.  
 
Given the substantial survival benefit with minimal side effect profile 
of targeted therapies, there should be a greater awareness in the 
medical education community to understand that even poor functional 
status patients with actionable mutations can benefit from these small 
molecule inhibitors. Furthermore, with the paradigm shift of 
immunotherapies in oncology where the goal is stimulation of the 
immune system, rather than immunosuppression as more classically 
taught with immune modulators, there should be greater education in 
learning about these mechanisms and immune-related adverse events. 
 
One additional consideration for this new generation of therapies is the 
cost to the patient and the healthcare system. There are some studies 
that suggest that first-line pembrolizumab and consolidation 
durvalumab are cost-effective with a similar conclusion for EGFR+ and 
ALK translocation directed therapies in NSCLC.59–65 Future studies will 
help identify patients who can most benefit from these next-generation 
therapies and help minimize toxicities and undue financial burden. 
 
 
Figure 1. Treatment Algorithm for Advanced NSCLC. 
 
 
 
Legend: The treatment of patients with advanced NSCLC is detailed here in the first-and second-line setting. Patients with no identifiable driver mutations follow along the 
treatment course on the left, while patients with EGFR/ALK/BRAF/ROS1 molecular alterations follow the right side. Patients with NSCLCs that carry BRAF and NTRK molecular 
alterations were excluded from this algorithm as there is not enough evidence to suggest a straightforward treatment path and will be up to the discretion of the treating 
physician based on evidence discussed above. All treatment decisions should be tailored to a patient’s specific performance status, biomarkers, prior treatments and the 
physician’s clinical judgement. Parts of the figures were adapted from the Society of Immunotherapy, see reference 53, Herbst RS, Davies MJ, Neal JW, Sagorsky S, Gandhi L, 
Antonia SJ, et al. and The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother 
Cancer. 2018;6(1):1–15), while the targeted therapy part was adapted from the studies in this paper. 
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